Sihuan Pharmaceutical: Hui Sheng Biomedical's self-developed GLP-1R/GCGR dual-target innovative drug P052 injection approved for clinical trials.

On September 9th, Sihuan Pharmaceutical announced on the Hong Kong Stock Exchange that its non-wholly-owned subsidiary, Huisheng Biopharmaceutical Co., Ltd., has obtained implied approval for the clinical trial application of the innovative drug P052 injection, a dual-target agonist of glucagon-like peptide-1 receptor/glucagon receptor, independently developed by the company, from the Drug Evaluation Center of the National Medical Products Administration. The drug is intended for the treatment of type 2 diabetes, overweight, or obesity. The P052 injection can not only promote insulin secretion, lower blood sugar, and reduce weight by stimulating the GLP-1 receptor, but also increase energy consumption, enhance weight loss efficacy, and improve liver fat metabolism by stimulating the GCGR. Preclinical data has shown that the hypoglycemic effect of the dual-target innovative drug P052 injection targeting GLP-1R/GCGR is similar to the GLP-1 single-target drug liraglutide injection, with a significantly better weight loss effect than liraglutide injection.